After weeks of anticipation, both the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have now weighed in on COVID-19 booster shots. And they’ve decided that four groups of people, which includes a huge swath of the population, should be eligible for the shots.
- People who are 65 years and older and those who live in long-term care facilities should get booster shots.
- People who are between the ages of 50 and 64 who have an underlying medical condition that puts them at risk for severe COVID-19 symptoms should get a booster shot.
- Those who are between the ages of 18 and 49 who have an underlying medical condition that makes them more likely to develop severe COVID-19 symptoms may get a booster shot if they wish, depending on their individual potential risks and benefits of the shot.
- People between the ages of 18 and 49 who face an increased risk for COVID-19 exposure and transmission due to their occupational or institutional setting may receive a booster shot if they want. But the decision to do so depends on the risks and benefits of the shot for each individual.
For all of these groups, the recommendations only apply to those who received a Pfizer/BioNTech COVID-19 vaccine for their first doses. And they can only get a booster dose if it’s been at least six months since their first shots. Neither the FDA nor the CDC has ruled yet on whether or not it’s okay for people to mix and match which vaccines they get (if, for instance, someone got the Moderna vaccine initially and gets a Pfizer booster shot).
The COVID-19 booster shot conversation kicked off in the U.S. in earnest when the White House announced a plan to offer third vaccine doses to the general public last month. Based on data mainly from Israel, it appeared that protection against COVID-19 infections (but not so much against hospitalization and death) was waning among those who received their first shots early on. After an FDA advisory panel recommended authorizing Pfizer booster doses for specific groups of people (primarily those over age 65), the agency updated the vaccine’s emergency use authorization to allow that use. Then, over the past two days, the CDC’s Advisory Committee on Immunization Practices (ACIP) met to discuss the potential recommendations around who should actually receive booster doses.
Some of the most compelling evidence for the use of COVID-19 booster shots that ACIP saw yesterday was for older populations, many of whom were prioritized during the initial vaccine rollout phase and are generally at a higher risk for severe complications from the virus. The panel weighed the potential benefits and risks of administering third doses to other age groups (including the risk for myocarditis, which is most likely to affect young men), underlying medical conditions, and certain occupational risk factors that make them more likely to be exposed to the virus (especially with the highly transmissible delta variant now dominant in the country).